• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Japan-based Fujirebio Diagnostics Expands Facility in Malvern, Pennsylvania

Fujirebio Diagnostics, Inc., a Japan-based manufacturer of in vitro diagnostics, will expand its operations in Chester County, Pennsylvania. The company plans to create 41 new jobs while retaining 348.

According to state officials, the company will expand its existing location in Malvern and will reconfigure a significant portion of that space to accommodate additional manufacturing. The expansion will support the creation of 41 new jobs in positions for lab technicians, manufacturing engineers, process design scientists and management. The company has pledged to invest $7.74 million into the project.

“Fujirebio Diagnostics, Inc., is thankful for the strong relationship that we have continued to build over many years with the Commonwealth of Pennsylvania,” said Jenny Graham, CFO of Fujirebio Diagnostics. “This investment will help increase capacity and hire talented workers and is critical in ensuring that we continue to innovate, develop and provide the highest quality products as possible.”

Fujirebio Diagnostics received a funding proposal from the Department of Community and Economic Development (DCED) for a $185,000 Pennsylvania First grant and $123,000 in Job Creation Tax Credits to be distributed upon creation of the new jobs. The project was coordinated by the Governor’s Action Team, an experienced group of economic development professionals who report directly to the governor and work with businesses that are considering locating or expanding in Pennsylvania.

“Fujirebio Diagnostics is a longstanding Chester County company that has been a part of the community for more than 20 years,” said Governor Tom Wolf. “Their expansion will bring new opportunities and competitive wages to the region and enhance southeast Pennsylvania’s life science community.”

Fujirebio Diagnostics is owned by Fujirebio Holdings, Inc., which is owned by Japan-based Miraca Holdings, Inc., and develops and manufactures IVD test kits primarily used for cancer treatments. The company’s IVD product line ranges from highly specialized manual testing kits to fully automated routine clinical laboratory testing solutions. In addition to its own product lines, Fujirebio also produces test kits for third party customers.

Exclusive Research